BIOX-101 (Ir-CPI)

About Bioxodes

Bioxodes is a Belgian biotech focused on addressing significant unmet needs in stroke, particularly intracerebral hemorrhage (ICH), which currently has no approved therapy. Its lead asset, BIOX-101, is a first-in-class drug with a dual mechanism inhibiting neutrophil extracellular traps (NETs) and coagulation factors XIa/XIIa, aiming to prevent secondary damage without increasing bleeding risk. The company is preparing for a potentially pivotal Phase 2b trial in ICH and exploring expansion into ischemic stroke and other chronic inflammatory conditions. With Orphan Drug Designation in the US and EU, Bioxodes is positioning its novel platform as a breakthrough in thrombo-inflammation.

About Bioxodes

Bioxodes is a Belgian biotech focused on addressing significant unmet needs in stroke, particularly intracerebral hemorrhage (ICH), which currently has no approved therapy. Its lead asset, BIOX-101, is a first-in-class drug with a dual mechanism inhibiting neutrophil extracellular traps (NETs) and coagulation factors XIa/XIIa, aiming to prevent secondary damage without increasing bleeding risk. The company is preparing for a potentially pivotal Phase 2b trial in ICH and exploring expansion into ischemic stroke and other chronic inflammatory conditions. With Orphan Drug Designation in the US and EU, Bioxodes is positioning its novel platform as a breakthrough in thrombo-inflammation.

Therapeutic Areas